Evidence map›Paper›PMID 33384594›Full record

ArticleFrontiers in aging neuroscience2020

Posterior Cingulate Cortex Network Predicts Alzheimer's Disease Progression.

Pei-Lin Lee, Kun-Hsien Chou, Chih-Ping Chung, Tzu-Hsien Lai, Juan Helen Zhou, Pei-Ning Wang, Ching-Po Lin

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07667478 (NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07667478 narecruitingnot on this mapstarted 2026, after this paper: background citation

Non-invasive brain stimulation for memory loss in early alzheimer's disease

TypeinterventionalSponsorChi-Ying (Roy) LinRan2026 to 2031Enrolled40ConditionsAlzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild DementiaArmsrepetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Pei-Lin LeeInstitute of Neuroscience, National Yang-Ming University, Taipei, Taiwan.
Kun-Hsien ChouInstitute of Neuroscience, National Yang-Ming University, Taipei, Taiwan.
Chih-Ping ChungDepartment of Neurology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Tzu-Hsien LaiDepartment of Neurology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Juan Helen ZhouDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Pei-Ning WangBrain Research Center, National Yang-Ming University, Taipei, Taiwan.
Ching-Po LinInstitute of Neuroscience, National Yang-Ming University, Taipei, Taiwan.
National Yang Ming Chiao Tung University · TWNational Yang Ming Chiao Tung University · TWNational University of Singapore · SGTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of toxic misfolded proteins, which are believed to have propagated from disease-specific epicenters through their corresponding large-scale structural networks in the brain. Although previous cross-sectional studies have identified potential AD-associated epicenters and corresponding brain networks, it is unclear whether these networks are associated with disease progression. Hence, this study aims to identify the most vulnerable epicenters and corresponding large-scale structural networks involved in the early stages of AD and to evaluate its associations with multiple cognitive domains using longitudinal study design. Annual neuropsychological and MRI assessments were obtained from 23 patients with AD, 37 patients with amnestic mild cognitive impairment (MCI), and 33 healthy controls (HC) for 3 years. Candidate epicenters were identified as regions with faster decline rate in the gray matter volume (GMV) in patients with MCI who progressed to AD as compared to those regions in patients without progression. These epicenters were then further used as pre-defined regions of interest to map the synchronized degeneration network (SDN) in HCs. Spatial similarity, network preference and clinical association analyses were used to evaluate the specific roles of the identified SDNs. Our results demonstrated that the hippocampus and posterior cingulate cortex (PCC) were the most vulnerable AD-associated epicenters. The corresponding PCC-SDN showed significant spatial association with the patterns of GMV atrophy rate in each patient group and the overlap of these patterns was more evident in the advanced stages of the disease. Furthermore, individuals with a higher GMV atrophy rate of the PCC-SDN also showed faster decline in multiple cognitive domains. In conclusion, our findings suggest the PCC and hippocampus are two vulnerable regions involved early in AD pathophysiology. However, the PCC-SDN, but not hippocampus-SDN, was more closely associated with AD progression. These results may provide insight into the pathophysiology of AD from large-scale network perspective.

Indexed as

Alzheimer's diseasehippocampusmild cognitive impairmentposterior cingulate cortexstructural covariance networksynchronized degeneration network

Identifiers

PMID33384594
PMCPMC7770227
OpenAlexW3111008324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.